On The Money Is this stock market theme a big opportunity or a bubble?
A new generation of weight-loss drugs have proved appetising to investors, with the two companies currently dominating the market enjoying strong share price gains over the past few years. Other firms are also poised to join the trend, which is expected to expand significantly by 2030. However, does the hype risk creating an obesity-drug bubble? Joining Kyle to answer that question and discuss the outlook for the theme is Ailsa Craig, manager of International Biotechnology Trust. Ailsa also names themes she’s favouring in biotech and explains why she’s optimistic the sector will bounce back from its worst-ever bear market.
On The Money is an interactive investor (ii) podcast. For more investment news and ideas, visit www.ii.co.uk/stock-market-news.
Kyle Caldwell is Collectives Editor at interactive investor.
Important information:
This material is intended for educational purposes only and is not investment research or a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy. The value of your investments can rise as well as fall, and you could get back less than you invested. Past performance is not a guide to future performance. The investments referred to may not be suitable for all investors, and if in doubt, you should seek advice from a qualified investment adviser. SIPPs are aimed at people happy to make their own investment decisions. Investment value can go up or down and you could get back less than you invest. You can normally only access the money from age 55 (57 from 2028). We recommend seeking advice from a suitably qualified financial adviser before making any decisions. Pension and tax rules depend on your circumstances and may change in future. If you are in any doubt about the suitability of a Stocks & Shares ISA, you should seek independent financial advice. The tax treatment of this product depends on your individual circumstances and may change in future. If you are uncertain about the tax treatment of these products, you should contact HMRC or seek independent tax advice. Interactive Investor Services Limited is authorised and regulated by the Financial Conduct Authority.